Molsidomin Stada (Molsidomine)

Molsidomine, the active ingredient in Molsidomin Stada, is a nitric oxide donor presented as an oral tablet for oral use. It is employed in the management of chronic stable angina and other forms of ischemic heart disease in adult patients.

GNH USA supplies Molsidomin Stada as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, ensuring consistent quality and regulatory compliance across markets.

Molsidomin is used in the cardiovascular disease pathway to relieve myocardial ischemia. - Chronic stable angina: reduces frequency of angina attacks and improves exercise tolerance. - Ischemic heart disease: decreases myocardial oxygen demand through vasodilation. - Angina pectoris: alleviates chest pain associated with reduced coronary blood flow.

Molsidomin may be associated with several adverse reactions, ranging from mild to serious.

Common Side Effects: - Headache: mild to moderate intensity, often transient. - Flushing: warmth and redness of the skin. - Dizziness: sensation of light‑headedness, especially on standing. - Nausea: mild gastrointestinal upset. - Hypotension: low blood pressure causing faintness.

Serious or Rare Side Effects: - Severe hypotension: marked drop in blood pressure requiring medical intervention. - Syncope: sudden loss of consciousness. - Allergic reactions: rash, pruritus, or angioedema. - Myocardial infarction: rare occurrence despite anti‑anginal use.

When prescribing Molsidomin, clinicians should consider several precautionary measures to ensure patient safety. - Cardiovascular status: assess for existing hypotension before initiating therapy. - Concomitant nitrates: avoid co‑administration to prevent additive vasodilation. - Renal impairment: use with caution in patients with severe renal dysfunction. - Hepatic impairment: monitor liver function as metabolism occurs hepatically. - Elderly patients: start at lower doses and monitor for dizziness or falls. - Store at room temperature: keep below 25 °C, retain in original packaging, protect from moisture and direct sunlight.

Molsidomin can interact with other medicines, influencing its efficacy or safety profile.

Major Interactions (Avoid): - Nitrates (e.g., nitroglycerin): combined use may cause profound hypotension. - Phosphodiesterase‑5 inhibitors (e.g., sildenafil): risk of severe blood pressure fall.

Moderate Interactions (Monitor Closely): - Antihypertensives (e.g., ACE inhibitors, beta‑blockers): may enhance blood‑pressure‑lowering effect. - Diuretics: potential additive hypotensive effect. - Alcohol: can increase risk of dizziness and hypotension.